Printer-Friendly
Lithostat® (acetohydroxamic acid) is indicated as adjunctive therapy with antimicrobial agents for the treatment of chronic urea-splitting urinary infection. AHA reversibly inhibits the bacterial enzyme urease, thereby inhibiting the hydrolysis of urea and productin of ammonia in urine infected with urea-slitting organisms. This combined therapy allows an increased cure rate of
Urology
Thiola®
Thiola® (tiopronin) is indicated for the prevention of cystine (kidney) stone formation. It is an alternative therapeutic approach for patients with severe homozygous cystinuria with urinary cystine greater than 500 mg/day who are resistant to diet modification and high fluid intake.
Uribel™
Uribel™ provides a combination of analgesic, antispasmodic, and antiseptic therapies to relieve local discomfort caused by: lower urinary tract infections (UTIs), interstitial cystitis (IC), painful bladder syndrome (PBS), and prediagnostic and postdiagnostic procedures. Uribel™ is genrally well tolerated and can symptom relief can begin in as little as 30 minutes.
Urocit®-K
Urocit®-K (extended release potassium citrate) inhibits formation of both calcium oxalate and uric acid (kidney) stones. Urocit®-K is indicated for the management of renal tubular acidosis with calcium stones, hypocitraturic calcium oxalate nephrolithiasis of any etiology, and uric acid lithiasis with or without calcium stones.